Purpose. Candida albicans and Staphylococcus aureus can be co-isolated in biofilm-associated infections. However, treatments have not been well established due to a lack of antibiofilm strategies. Hence, this study aims to characterize the mechanism and impact of Staphylokinase (Sak) on fungal-bacterial polymicrobial biofilms.
INTRODUCTION
Microbial biofilms formed on implanted medical devices are associated with numerous infections resulting in an enormous burden to healthcare systems, due to their extreme resistance to antibiotics [1] . Alarmingly, infections caused by polymicrobial biofilms in neonatal sepsis have caused a significantly higher mortality rate (70 %) compared to infections by a single species of micro-organism (23 %) [2] . To date, Candida albicans has been recognized as the leading fungal pathogen responsible for severe systemic infections in hospitalized patients, and often co-exists in polymicrobial biofilms with bacterial pathogens such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa and various Streptococcus species, especially S. aureus [3, 4] . Importantly, approximately 27 % of candidaemia infections are polymicrobial, with S. aureus representing the third most frequently co-isolated organism, which results in severe morbidity and mortality in hospitalized patients [5] [6] [7] . In vivo studies demonstrated that mice inoculated with S. aureus alone exhibited lower mortality compared to the co-inoculation with C. albicans [8, 9] . Furthermore, a recent study reported that co-infection caused by these micro-organisms led to a 40 % mortality, which increased the microbial burden of the spleen and kidney by day 1 post-infection [9] . Thus, the interplay between C. albicans and S. aureus in vivo appears to be mutually beneficial but harmful to the hosts.
Not only are these pathogens responsible for a substantial number of severe and acute infections independently, they have also been reported to co-exist in the polymicrobial biofilms on the surfaces of various biomaterials, including dentures, voice prostheses, implants, endotracheal tubes, feeding tubes, and most commonly, catheters [10] . It is estimated that over half of hospital infections are derived from biofilms of microbial communities [11] . If polymicrobial biofilm infections were suspected, removal of the infected device and the use of antimicrobial lock are standard procedures in the current strategies [4] . However, ill patients are often unable to tolerate these procedures, leaving limited treatment choices for these cases [4] . Therefore, these patients should be treated with new substances and antimicrobial combinations in a more effective way [3, 4, 12] .
Staphylokinase (Sak) is a plasminogen activator secreted by S. aureus strains [13] . By inducing cleavage of host-derived fibrin, Sak prevents S. aureus from attaching to surfaces, thereby restricting the subsequent formation of a biofilm matrix. Bacteria presented in biofilms become less sensitive to antimicrobials due to several factors, including limited penetration of an antibiotic agent into a biofilm matrix [4] . While in the mature biofilms, Sak induces detachment of a mixed-species biofilm by degrading the fibrin scaffold that assembles biofilms [14] . Therefore, inclusion of Sak into routine combination treatment strategies could lead to easier disruption of the biofilm structure and better penetration of the antimicrobial agents to kill the bacteria and fungi, thereby ultimately improving patient outcomes. Consequently, antimicrobial combinations with Sak may be much more beneficial to the immunocompromised patients when compared to the treatment of removing the medical device. Although some studies have evaluated the impact of Sak against monomicrobial species biofilms, limited data has been reported concerning the roles of Sak against fungalbacterial polymicrobial biofilms.
To the best of our knowledge, this is the first study revealing that Sak can reduce polymicrobial biofilms formed by C. albicans and S. aureus through decreasing biomass and biofilm integrity and inhibiting the metabolic activity and early stage growth. Understanding the mechanisms of Sak in decreasing the C. albicans and S. aureus polymicrobial biofilms and discerning the variation of the metabolic activity, growth rate, adhered ability, integrity and total biomass will lay a foundation for the treatment of deadly infections associated with polymicrobial biofilms.
METHODS
Strains and media C. albicans strain SC5314 (kindly provided by Dr Yue Qu, Monash University, Australia), ten clinical Sak-producing S. aureus strains (JP275, JP280, JP281, JP738, JP749, JP769, JP809, JP822, JP839 and JP841) and ten clinical Saknonproducing S. aureus strains (JP159, JP163, JP182, JP185,  JP198, JP642, JP673, JP694, JP744 and JP751) were collected from the First Affiliated Hospital of Wenzhou Medical University and utilized in this study. In biofilm formation and integrity experiments, Trypticase soy broth (TSB, Oxoid, Hampshire, UK) with 0.5 % glucose (Sinopharm, Shanghai, China) was used alone or supplemented with human plasminogen (0.01 mg ml
À1
, BJ40286, Guangzhou, China). For metabolic mitochondrial activity, growth rate, adhesion ability and quantification RT-PCR (qRT-PCR) assays, TSB with plasma and 0.5 % glucose was used alone or supplemented with 10 µg ml À1 recombinant Sak (PrimeGene, Shanghai, China), which is purified from Escherichia coli and stable in the incubation temperatures. Microbial load was the same in all experiments. In the case of the 48 h biofilms, fresh medium was added after the first 24 h.
Measurement of the Sak generation level of S. aureus
Ten clinical Sak-producing S. aureus strains were subjected to measure the secretion levels using a chromogenic experiment, as described [15] . Briefly, S. aureus strains were grown in 4 ml Luria-Bertani (LB) for 18 h, with shaking at 35 C. Overnight cultures were centrifuged at 4000 g for 10 min at 4 C to collect supernatants. Then, a 30 µl supernatant was mixed with 50 µl 0.04 mg ml À1 human glu-plasminogen, followed by incubation for 20 min at 37 C. Then, 20 µl plasmin-specific chromogenic substrate S-2251 (Boatman Biotech, Shanghai, China) was added. OD 405 was measured with an Infinite M200 plate reader over a 1 h period of incubation at 37 C. Absorbance of more than 0.05 was regarded as Sak positive. Two Sak-nonproducing strains (JP159 and JP751) were used as a negative control.
Quantification of the total biofilm biomass
To explore whether the biofilm formation is negatively affected by Sak generation, biofilm formation capacity was assessed between two groups (Sak-nonproducing and Sakproducing groups) according to Aubin et al. with some modifications [16] . Specifically, C. albicans and S. aureus polymicrobial biofilms were created by micro-organisms to 1Â10 6 c.f.u. ml À1 in TSB, added equal inoculum (10 µl) of each strain to a fresh TSB (180 µl) using a 96-well polystyrene tissue culture-treated microplate (Costar, Corning, NY, USA). The plate was then inoculated at 37 C aerobically under static conditions. Each group was inoculated under two different growth conditions (i.e. with and without human plasminogen). After 24 and 48 h of biofilm formation, the nonadherent cells were removed and then washed with 200 µl PBS (Sigma, USA) three times using a micropipette (Eppendorf, Germany) and air-dried. We then fixed the biofilms with 200 µl of 100 % methanol (Lingfeng, Shanghai, China) for 15 min. Biofilms were washed gently twice with PBS and stained with 200 µl 1 % crystal violet (Beyotime, Biotechnology, China) for 10 min. The stained biofilms were rinsed with PBS (three times) to remove the excess stain and dried. Next, 100 µl 100 % ethanol (Ante, Anhui, China) was then added to release and dissolve the remaining stain after 5 min incubation. The optical density was read and obtained using a microtitre plate reader (Diatek, DR-200B, Jiangsu, China) at 600 nm. Results were reported as the average values of three independent experiments.
Assessment of biofilm integrity
After 24 and 48 h of biofilm formation of the ten Sak-nonproducing and ten Sak-producing strains described previously, the medium was discarded and washed gently with PBS, in order to remove detached cells. Then we added 200 µl PBS before the biofilm was agitated gently via the vortex for 10 s. The supernatants were collected and we observed ten fields under a microscope (Olympus, Japan) at Â1000 magnifications after staining with crystal violet [17] .
Experiments were performed in triplicate and representative images were shown.
Scanning electron microscopy (SEM)
To further confirm the role of Sak on C. albicans biofims and polymicrobial biofilms, SEM was conducted using stainless steel pieces. C. albicans strain SC5314 was grown in single-species biofilms or with Sak-nonproducing S. aureus strain JP163 or Sak-producing S. aureus strain JP769 in mixed biofilms utilizing TSB for 24 h at 37 C with and without exogenous Sak (10 µg ml À1 ), as described elsewhere [17] . Samples were fixed in 2.5 % glutaraldehyde for 2 h, and then exposed to increasing concentrations of ethanol (50 , 70 , 80 , 90 , 100 %) for 10 min each. Biofilms were then dried with hexamethyldisilazane and coated with gold. The biofilms on stainless steel were examined with a SEM (Hitachi S-3000N, Japan). Images were captured at Â2000 magnification.
Metabolic mitochondrial activity analysis
The analysis of metabolic mitochondrial activity was conducted as previously reported in the study of Walencka et al. with minor modifications [18] . Ten Sak-nonproducing S. aureus strains were chosen. In brief, after the biofilms were cultured in 24 and 48 h (the same as described above) with or without Sak (10 µg ml À1 ), the wells of the microplate were emptied and washed three times with 1ÂPBS, then 150 µl of PBS was added into the wells. Next we added 50 µl of 3-[4,5-dimethylthiazol-2-yl]À2,5-diphenyltetrazolium bromide (MTT, Biomart, Beijing) solution (0.3 % in PBS) into the wells and incubated it for 2 h at 37 C. Before the optical density was read in a microtitre plate reader at 550 nm, MTT was replaced with 150 µL of dimethyl sulfoxide (DMSO, D1594, Fisher, USA) and 25 µl of glycine buffer (0.1 M, PH 10.2, MYM Biological Technology, India) and incubated for 15 min at 37 C with gentle agitation to dissolve formed purple formazan crystals. The data shown are the results of three independent assays. 
ACT1-R GACAATTTCTCTTTCAGCACTAGTAGTGA *Tm, melting temperature; F, forward (5¢) primer; R, reverse (3¢) primer. 
Assessment of growth rates
To identify the function of Sak, we evaluated its effects on micro-organism growth (cells in polymicrobial biofilms) in various stages [3, 19, 20] . Ten Sak-nonproducing S. aureus strains were selected to measure the growth kinetics with or without Sak (10 µg ml
À1
). Having grown for various lengths of time (3-7 h and 27-31 h) at 35 C with agitation at 300 r. p.m., the wells of the microplate were emptied and washed gently using PBS at each time point for polymicrobial biofilms. Then biofilms were scraped into 2 ml of PBS and then sonicated three times for 5 min at 37 kHz (Fisher Scientific, USA) and vortexed between each sonication. After suspension, 100-µl aliquots were transferred into a 96-well microtitre plate and cell density was measured using a microtitre plate reader at 600 nm (OD 600 ), as suggested in the study of and Stewart et al. [9, 19] . Results were given as percentages of untreated growth of three independent experiments.
Additionally, Sak-nonproducing S. aureus strain JP163 and Sak-producing S. aureus strain JP769 were further chosen to conduct a corresponding assay in the presence or absence of Sak. The experimental setup was exactly the same as that described above, except that 1 ml aliquots were diluted and plated on chromogenic medium for c.f.u. count. Colonies were counted and expressed as the number of c.f.u. ml À1 of three experiments.
Quantification of adhered biofilm cells
For experiments assessing the effect of Sak on adhesion ability, the experimental setup was exactly the same as that described above, except that the selected strains (ten Saknonproducing S. aureus strains) and incubation time (1 h). After incubation, the medium was discarded from each well. Then the adhered biofilms were scraped off carefully into 1ÂPBS with a sterile scraper (Corning, NY, USA) and then vigorously vortexed, in order to separate aggregation cells. 
Determination of C. albicans gene expression
To determine the roles of Sak in gene expression levels in 24 and 48 h, several genes from C. albicans related to adhesion, biofilm formation were carefully examined. Total RNAs were extracted using a Qiagen RNeasy Mini kit in accordance with the manufacturer's instructions. RNA concentrations were tested by a spectrophotometer at 260 nm (Thermo Scientific NanoDrop 2000, USA). cDNA synthesis was conducted using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit according to the manufacturer's instructions. The reaction mixture was incubated for annealing at 65 C for 5 min, extension at 42 C for 60 min and inactivation of samples at 70 C for 5 min. qRT-PCR was performed using a 7500 RT-PCR system and SYBR Green RT-PCR Kit (TOYOBO, Japan) with the specific primers (refer to Table 1) [21] . Briefly, the relative expression levels of ALS3, HWP1, EFG1 and NRG1 (target genes) were normalized with the ACT1 gene as a housekeeping gene, and then amplified from the same sample simultaneously. Cycling conditions were as follows: 95 C for 60 s followed by 40 cycles of 95 C for 15 s and 60 C for 60 s. Each sample was run in triplicate and the means of Ct values were used for analysis. Quantification of the target genes was analysed using the comparative threshold cycle 2 -DDCt method. All qRT-PCR sample reactions were performed in triplicate independently.
Biofilm antimicrobial susceptibility testing
The impact of Sak on C. albicans strain SC5314 alone or in combination with vancomycin was assessed in biofilm grown. Polymicrobial biofilms were grown using Sak-nonproducing S. aureus strain JP163 or Sak-producing S. aureus strain JP769, and C. albicans strain SC5314 for 24 h [16] . Following washing, the wells were added to fresh TSB supplemented with Sak, human plasminogen and vancomycin, the final concentration of vancomycin was 800 µg ml À1 . Plates were incubated for an additional 24 h at 37 C. Then biofilms were washed three times with PBS, and 100 µl PBS was added. Cells were separated via sonication followed by vortexing and pipetting. Cell suspensions were diluted and plated on Sabouraud Dextrose Agar plates for c.f.u. count. Drug-free wells were considered as a control. Additionally, the role of Sak on S. aureus strain JP163 or S. aureus strain JP769 alone as well as in combination with vancomycin was also tested as experimental controls. Further, susceptibility testing using fluconazole (128 mg ml À1 ) in S. aureus monomicrobial biofilm or utilizing both vancomycin and fluconazole in mixed biofilms were also performed [22] . Experiment was performed in biological triplicate and repeated three times.
Statistical analysis
Data were analysed using the Prism software package (GraphPad Software version 6.0). The results of the CV, OD 600 , MTT, Ct and biofilm antimicrobial susceptibility testing were compared using Student's t-test; while the percentage of cells attached was analysed by the chi-square test. Results with P-values<0.05 were considered to be statistically significant in our study.
RESULTS
Evaluation of Sak secretion levels in S. aureus clinical isolates S. aureus clinical isolates could produce different levels of Sak. As shown in Fig. 1 , the secretion levels of two Sak-nonproducing S. aureus strains JP163 and JP751 were both less than 0.005 (optical density increased was very low). Furthermore, ten clinical Sak-producing S. aureus strains generated varying levels of Sak, ranging from 0.130 to a relatively high level of 0.648.
Inhibition of biomass and integrity of C. albicans and S. aureus polymicrobial biofilms under Sak treatment To test whether there is a negative correlation between Sak treatment and S. aureus biofilm formation, we measured biofilm formation ability in broth supplemented with human plasminogen. Strikingly, the biofilm formation capability of Sak-producing S. aureus and C. albicans polymicrobial biofilms declined significantly, with a more significant decrease at 48 h than that at 24 h. However, the biomass of Sak-nonproducing S. aureus and C. albicans seemed to insignificantly change according to the reduced percentages in Table 2 .
To evaluate the effect of Sak on the integrity of S. aureus and C. albicans polymicrobial biofilms, the numbers of aggregates of the Sak-nonproducing S. aureus group and the Sak-producing S. aureus group in the supernatants were viewed under a microscope. In the biofilm integrity experiment incorporating human plasminogen, obvious differences could be observed between the strains (Fig. 2) . After Sak treatment, the integrity of polymicrobial biofilms was destroyed, aggregates could be seen in the supernatants. According to Fig. 2a, b , the Sak-nonproducing S. aureus group only released a few micro-organism aggregates in 24 and 48 h, respectively; while the Sak-producing S. aureus group released a greater number of aggregates and also some C. albicans cells in 24 h and even after 48 h failed to form a complete biofilm (Fig. 2c, d) .
Analysis of the C. albicans monomicrobial and mixed-species biofilm architecture via SEM To further visualize the structure of the C. albicans biofilm alone and mix-species biofilms, biofilms were allowed to form for 24 h in the absence and presence of Sak (10 µg ml À1 ), and the formed biofilms were comparatively observed through SEM analysis. Images revealed that there was little impact for attachment of C. albicans cells to a stainless steel surface in monomicrobial and polymicrobial biofilms (Fig. 3) . Interestingly, on the untreated group, images of the dual-species biofilms showed the physical interaction between C. albicans and S. aureus that numerous S. aureus cells attached to the hyphae of C. albicans whereas the biofilms are disrupted, with a reduction of the formation of polymicrobial biofilm and a strong reduction of the number of cells when treated with Sak (Fig. 3) . In contrast to the S. aureus strain JP163 secreting quite a low level of Sak, S. aureus strain JP769 with a high amount of Sak failed to form a complete architecture of biofilm relatively. Also, the S. aureus strain JP769 only attached in sporadic small microcolonies (Fig. 3) .
Effect of Sak on metabolic mitochondrial activity of Sak-nonproducing S. aureus
The results of metabolic mitochondrial activity analysis were shown in Fig. 4 . Compared to the Sak-untreated control group, all other micro-organisms achieved a significant decrease (P<0.05) of the biofilm metabolic mitochondrial activity after the treatment of Sak at 24 h except JP163 (2.1 %), JP182 (À0.6 %) and JP673 (1.1 %). Of more significance, the reduction in metabolic activity was observed in all the groups except for JP163 (12.6 %) in the presence of the Sak at 48 h. In particular, it is possible to observe a more significant inhibition, reaching 40 % inhibition in most S. aureus clinical strains treated with Sak at 48 h. Inhibitory properties of Sak on growth rates of polymicrobial biofilm cells To investigate whether Sak supplementation impacts the growth rates of S. aureus isloates, growth rate and c.f.u. count about C. albicans and S. aureus polymicrobial biofilms were performed exogenously supplemented with Sak. Based on the data of Fig. 5a , b, it confirmed that the treatment with Sak had a typically antagonistic effect on microorganism growth in the early stage (3-7 h). Specifically, compared to no treatment, treatment with Sak significantly reduced the growth rates of polymicrobial biofilm cells ranging from 10 to 40 %. In contrast, after 27 h of Sak treatment, no obvious difference was shown between the treated and untreated group when the micro-organism reached the stable stage (27-31 h) (Fig. 5c, d) . The reduced percentages of growth rates were less than 10 % in the stable stage.
Similarly, assessment of S. aureus JP163 and JP769 viability via c.f.u. count manifested a significant decrease in the presence of Sak during 3-7 h (Fig. 5e, f) . However, no significant impact was noted during the period of 27-31 h after Sak treatment (Fig. 5e, f) . The c.f.u./ml À1 of S. aureus JP163 and JP769 strains were both 10 7 at 31 h approximately (Fig. 5e, f) .
Influence of Sak on adhered biofilm cells
In the C. albicans and S. aureus polymicrobial biofilms, the filamentous fungal network is the main framework with S. aureus interspersing within it. As shown in Table 3 , adhesion experiments in S. aureus revealed the adhesion percentages in the treated group and the untreated group were 11.8-18.4% and 12.6-18.0 %, respectively. There was a significant decrease only in JP163, JP642 and JP694 (P<0.05), whereas no significant difference in other S. aureus strains. Furthermore, the percentages of C. albicans adhesion between the treated group and the untreated group were among 34.9-36.8% and 34.5-38.7 %, respectively. There was no striking impact between the treated and untreated groups according to corresponding statistical data.
RNA extracted from Sak-treated biofilms was reverse transcribed, and qRT-PCR was performed on the most notable biofilm-related genes in C. albicans, i.e. ALS3, HWP1, EFG1 and NRG1. Gene expression was displayed as fold change. The experimental results demonstrated that Sak caused significant decreases in the expression of HWP1 and EFG1 (1.54-fold, 1.72-fold in 24 h and 3.03-fold, 3.70-fold in 48 h, respectively), and a significantly greater level of NRG1 expression than untreated biofilm, averaging a 2.20-fold and 5.54-fold increase in expression of 24 and 48 h, respectively (Fig. 6) . However, no significant alternation of expression in the ALS3 gene was observed (Fig. 6 ).
Therapeutic effect of Sak and antimicrobial combination treatment activity on monomicrobial and dual-species biofilms Based on the analysis of c.f.u. in Fig. 7a , C. albicans biofilms remained nearly identical with or without Sak (P>0.05). Also, vancomycin had no impact on C. albicans monomicrobial specie biofilm (P>0.05), fluconazole had no effect on S. aureus biofilm (data not shown). Moreover, Sak could diminish the c.f.u. of Sak-nonproducing S. aureus strain JP163 (P<0.05) or Sak-producing S. aureus strain JP769 (P<0.05) significantly. Likewise, vancomycin almost could kill both S. aureus strains (JP163 and JP769) alone (data not shown) or combining with Sak (P<0.05). In view of polymicrobial biofilms in Fig. 7b, c. f.u. counts showed a significant decrease under treatment with Sak, to a level comparable to that for C. albicans -bacterial mixed biofilms only. Importantly, data from these experiments revealed a combination of Sak and antibacterial drugs (vancomycin) have a more striking role in cell growth in biofilm lifestyle. In order to further identify the combination role of Sak, vancomycin and fluconazole together, similar experiments were also conducted. Data from these assays demonstrated that a significant decrease of c.f.u. was observed compared to Sak or antimicrobial treatment alone.
DISCUSSION
Polymicrobial infections, especially those correlated with biofilms formed on catheter surfaces caused by a mixed fungal-bacterial, are responsible for high mortality and morbidity [23] . It has been reported that the co-existing of S. aureus and C. albicans can form a substantial biofilm, where C. albicans serves as a scaffold for S. aureus in the formation of such biofilms, which are associated with the polymicrobial infections [24] . The recent literature has unraveled that Sak is capable of controlling the development and formation of S. aureus biofilms by activating plasmin(ogen)-dependent proteolysis and fibrinolysis [13] . Nevertheless, there are some significant differences between bacteria and yeast, in terms of relative cell size, morphology and biochemistry [25] . Therefore, deciphering the functions of Sak against C. albicans and S. aureus polymicrobial biofilms will form a basis for disrupting these complex mixed infections.
Bamford et al. had noted that the complex physical and chemical interactions between Streptococcus gordonii and C. albicans can contribute to an elevated biomass of co-inoculated biofilms using a crystal violet staining assay [26] . As previously reported, the higher quantity of glucose (a major component of the C. albicans matrix) can enhance the formation of biofilms [27] . Conversely, fibrin is a target of antibiofilm when C. albicans and Sak-producing S. aureus formed a polymicrobial biofilm. As expected, our study verified that the Sak-producing S. aureus strains formed significantly less polymicrobial biofilms with C. albicans than S. aureus strains without Sak generation. During this process, Sak could control the development of S. aureus biofilms via activating fibrinolysis, indicating that fibrinolysis might be a new strategy for disrupting those complex mixed biofilms. Furthermore, it is important to note that the generation of Sak in our experiments could occur in late exponential phase. These observations were in agreement with the study of Kwiecinski et al., however, the levels of Sak generation varied in our clinical S. aureus strains when compared with their report, which was probably correlated with the isolation of these strains from different geographical locations [14] .
Biofilm development involves the detachment of cells from the biofilm into the surrounding medium and subsequent dispersal of these cells to new environments. Biofilm dispersal is known to involve a complex interplay between various environmental, chemical and physical cues [28] . Based on our discovery, untreated polymicrobial biofilms only released a few micro-organism aggregates, whereas a single C. albicans biofilm released high levels of large hyphae following mild shear stress by the report of James et al. [21] . After the treatment of Sak, an abundance of C. albicans cells was found in the supernatants, suggesting both C. albicans and S. aureus were detached from the biofilms, thereby leading to the possibility of complete destruction of polymicrobial biofilm integrity. To address that issue, in this study we further emphasized by SEM. Indeed, it is in line with the study above suggesting Sak could diminish the attachment of S. aureus on C. albicans hypha, which revealed that fewer cells and cell agglomerates were more sparsely distributed on the C. albicans hypha. Interestingly, there was no striking effect on the attachment of C. albicans cells on the surface of material. Consequently, it is conceivable to speculate that Sak inhibited C. albicans and S. aureus polymicrobial biofilm infections mainly via separating the polymicrobial biofilm integrity rather than diminishing the attachment of C. albicans biofilm cells alone.
As previously reported, dual biofilms of C. albicans and S. aureus showed higher metabolic activity than the monomicrobial biofilm [29] . Our study validated that Sak could inhibit the metabolic activity of polymicrobial biofilms and the effect intensity is increased with the alteration of time.
The result of the present study corroborated that Sak could reduce the cell viability of these micro-organisms. Another notable finding of this study was that Sak has a significant inhibitory effect on the early stage of C. albicans and S. aureus polymicrobial growth. Such an inhibition might be due to the fact that Sak outcompetes the C. albicans cells as a toxic bacterial metabolic by-product in the growth medium [21] . This should be of important significance in clinical settings as avoiding the initial cell growth and further reducing the attachment of dual-species cells on the surface of materials to form a biofilm is an effective strategy to prevent following mature biofilm formation. However, the re-growth of JP 159, JP 182, JP 185, JP 642 and JP 673 might be caused by different surface properties in various strains, such as an extracellular matrix. The ability of Sak to diminish the growth rate and metabolic activity may have potential clinical implications for treatment and control of C. albicans and S. aureus polymicrobial infections.
Quantification of adhered C. albicans biofilm cells showed no notable difference between the Sak treated and untreated groups, which is presumably because fibrin of C. albicans is not the major target of antibiofilm action at this initial stage. However, the data from this investigation suggested that the adhered cells of three S. aureus strains were decreased, which might be due to diverse growth characteristics in clinical strains. Overall, our observations of SEM and quantification of adhered C. albicans and S. aureus biofilm cells demonstrated that Sak might play a role in mixed-species biofilm dispersal and inhibit the attachment of S. aureus on C. albicans hypha, however, had almost no effect on the adhesion of C. albicans cells on the material surface alone.
It is interesting to note that NRG1 was reported to encode the DNA-binding protein Nrg1p in C. albicans, which exerts an exquisite control of the dispersal process, as overexpression of NRG1 contributes to an increase in the dispersion of yeast cells from the biofilms [30] . This explains the up-regulation of NRG1 in our gene expression profiles. However, the ALS3 gene encodes the hypha-specific surface protein Als3, which mediates the adherence to diverse host substrates [31] . Intriguingly, our observation of the alteration of the ALS3 gene expression level was insignificant. Therefore, it is feasible to speculate that Sak may act as a substrate for Nrg1p, whereas no evident impact on the function of Als3 protein in C. albicans cells. Additionally, the EFG1 gene could encode the transcription factor Efg1p, which is a critical transcriptional activator for several hyphae-specific genes and essential for the yeast-hyphae transition [21] . Further, the HWP1 gene encodes the hyphal cell wall protein Hwp1p, which forms covalent bonds with host substrates [32] . Here, the down-regulation of these genes manifested that Sak could induce inhibition of biofilm formation and underpin the usage of Sak as an effective antibiofilm agent.
The most interesting results generated from this study came from assays assessing the effect of Sak and/or combination with antimicrobial treatment on monomicrobial and polymicrobial biofilms. In accordance with the study of SEM, Sak had no significant influence on C. albicans monomicrobial biofilm alone. In addition, no impact could be observed of vancomycin on the C. albicans biofilm. Likewise, fluconazole had no effect on the S. aureus biofilm. This should be caused by a different action target of antimicrobials in bacteria and fungal, respectively. Our observations, however, demonstrated that the role for the Sak in the destruction of biofilm integrity could promote better penetration of antimicrobial agents into the cells to kill the pathogens, further leading to a higher susceptibility of the biofilms to antifungal therapy. Indeed, vancomycin could diminish the C. albicans and S. aureus polymicrobial mature biofilms more significantly after the treatment of Sak when compared to Sak alone. Furthermore, results of antimicrobial combinations (vancomycin+fluconazole+Sak) revealed that combination treatment strategies were able to decrease the polymicrobial biofilm biomass significantly. These findings indicated that combinations of antifungal drug (fluconazole), antibacterial drug (vancomycin) and Sak for optimal activities against fungal-bacterial polymicrobial biofilms are essential for guiding the development of more efficient antibiofilm therapies in clinic. Importantly, it is crucial to develop appropriate animal models to study these phenomena in vivo, such as coating Sak and antimicrobials on the materials surface, to inhibit biofilm formation. Therefore, these findings are of important clinical significance.
Although we observed the activity of Sak against polymicrobial biofilm, we did not observe the impact of Sak on mixed-species biofilms from a better quantitative perspective via confocal laser scanning microscopy. Further studies are required to uncover the role of Sak on dual-species biofilms using an additional method, such as Confocal Laser Scanning Microscopy (CLSM), to quantify. Furthermore, in view of the complex nature of polymicrobial biofilms in clinic, the potential effect of Sak in mixed-species biofilms involving other bacterial species is also a limitation. Further understanding of the detailed role of Sak in the polymicrobial biofilms' formation of C. albicans and other bacterial species will allow for the identification of credible targets to treat polymicrobial biofilm infections.
Collectively, this study contributed to a better understanding of the mechanism and effect of Sak on the formation of C. albicans and S. aureus polymicrobial biofilms. Our findings are anticipated to provide a crucial perspective for developing new strategies and overcoming the limitations regarding the prevention, control and treatment of polymicrobial biofilm infections. Importantly, the identification of potential targets for the inhibition of mixed-species biofilms may ultimately provide the means to remedy microbial infection, reducing the impact of polymicrobial diseases on human health. 
